-
Something wrong with this record ?
Recovery of mucosal-associated invariant T cells after myeloablative chemotherapy and autologous peripheral blood stem cell transplantation
J. Novak, J. Dobrovolny, J. Brozova, L. Novakova, T. Kozak,
Language English Country Italy
Document type Journal Article
NLK
ProQuest Central
from 2002-05-01 to 2018-12-31
Medline Complete (EBSCOhost)
from 2003-05-01 to 1 year ago
Health & Medicine (ProQuest)
from 2002-05-01 to 2018-12-31
- MeSH
- Transplantation, Autologous methods MeSH
- C-Reactive Protein metabolism MeSH
- Cytarabine administration & dosage pharmacology MeSH
- Hematologic Neoplasms blood immunology therapy MeSH
- Carmustine administration & dosage pharmacology MeSH
- Middle Aged MeSH
- Humans MeSH
- Mucosal-Associated Invariant T Cells drug effects metabolism MeSH
- Melphalan administration & dosage pharmacology MeSH
- Myeloablative Agonists administration & dosage pharmacology MeSH
- Podophyllotoxin administration & dosage pharmacology MeSH
- Transplantation Conditioning methods MeSH
- Antineoplastic Combined Chemotherapy Protocols administration & dosage pharmacology MeSH
- Peripheral Blood Stem Cell Transplantation methods MeSH
- Age Factors MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
Immune reconstitution after high-dose chemotherapy and stem cell transplantation plays a key role in restoring immunocompetence including defense against infection, immune regulation, and onco-immune surveillance. In this work, we examined the recovery of mucosal-associated invariant T (MAIT) cells, recently discovered innate-like T cells, after various types of myeloablative chemotherapy and autologous peripheral blood stem cell transplantation in 29 patients. We show that MAIT cells are relatively resistant to myeloablative conditioning. The median amount of MAIT cells rises to 43 % around day +30 and is sustained through further measurements on days +60 and +100. Moreover, MAIT cell recovery reaches 100 % of pre-treatment values in 33 % of patients already by day +60. The only factor affecting recovery of MAIT cells is age, younger age being associated with earlier MAIT cell recovery. The pre-treatment quantity of MAIT cells carries a prognostic impact on the early post-transplantation course. Patients with high levels of MAIT cells pre-treatment have significantly lower peak CRP levels (79.45 vs. 150 mg/L) post-treatment, reflecting a clinical trend of less severe infectious complications (less febrile days and less days on intravenous antibiotics). Altogether these data suggest that a high proportion of MAIT cells survive myeloablative chemotherapy and maintain their capacity to fight against infections probably on mucosal surfaces.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17014253
- 003
- CZ-PrNML
- 005
- 20170427115519.0
- 007
- ta
- 008
- 170413s2016 it f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s10238-015-0384-z $2 doi
- 035 __
- $a (PubMed)26409838
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a it
- 100 1_
- $a Novak, Jan $u Department of Immunology, 3rd Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. novakjan@centrum.cz. Department of Internal Medicine and Haematology, 3rd Faculty of Medicine, Charles University in Prague and Faculty Hospital Kralovske Vinohrady, Srobarova 50, 100 34, Prague 10, Czech Republic. novakjan@centrum.cz.
- 245 10
- $a Recovery of mucosal-associated invariant T cells after myeloablative chemotherapy and autologous peripheral blood stem cell transplantation / $c J. Novak, J. Dobrovolny, J. Brozova, L. Novakova, T. Kozak,
- 520 9_
- $a Immune reconstitution after high-dose chemotherapy and stem cell transplantation plays a key role in restoring immunocompetence including defense against infection, immune regulation, and onco-immune surveillance. In this work, we examined the recovery of mucosal-associated invariant T (MAIT) cells, recently discovered innate-like T cells, after various types of myeloablative chemotherapy and autologous peripheral blood stem cell transplantation in 29 patients. We show that MAIT cells are relatively resistant to myeloablative conditioning. The median amount of MAIT cells rises to 43 % around day +30 and is sustained through further measurements on days +60 and +100. Moreover, MAIT cell recovery reaches 100 % of pre-treatment values in 33 % of patients already by day +60. The only factor affecting recovery of MAIT cells is age, younger age being associated with earlier MAIT cell recovery. The pre-treatment quantity of MAIT cells carries a prognostic impact on the early post-transplantation course. Patients with high levels of MAIT cells pre-treatment have significantly lower peak CRP levels (79.45 vs. 150 mg/L) post-treatment, reflecting a clinical trend of less severe infectious complications (less febrile days and less days on intravenous antibiotics). Altogether these data suggest that a high proportion of MAIT cells survive myeloablative chemotherapy and maintain their capacity to fight against infections probably on mucosal surfaces.
- 650 _2
- $a věkové faktory $7 D000367
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x aplikace a dávkování $x farmakologie $7 D000971
- 650 _2
- $a C-reaktivní protein $x metabolismus $7 D002097
- 650 _2
- $a karmustin $x aplikace a dávkování $x farmakologie $7 D002330
- 650 _2
- $a cytarabin $x aplikace a dávkování $x farmakologie $7 D003561
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a hematologické nádory $x krev $x imunologie $x terapie $7 D019337
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a melfalan $x aplikace a dávkování $x farmakologie $7 D008558
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a MAIT buňky $x účinky léků $x metabolismus $7 D000072336
- 650 _2
- $a myeloablativní agonisté $x aplikace a dávkování $x farmakologie $7 D019653
- 650 _2
- $a transplantace periferních kmenových buněk $x metody $7 D036102
- 650 _2
- $a podofylotoxin $x aplikace a dávkování $x farmakologie $7 D011034
- 650 _2
- $a příprava pacienta k transplantaci $x metody $7 D019172
- 650 _2
- $a autologní transplantace $x metody $7 D014182
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Dobrovolny, Jan $u Department of Internal Medicine and Haematology, 3rd Faculty of Medicine, Charles University in Prague and Faculty Hospital Kralovske Vinohrady, Srobarova 50, 100 34, Prague 10, Czech Republic.
- 700 1_
- $a Brozova, Jitka $u Department of Immunology, 3rd Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
- 700 1_
- $a Novakova, Lucie $u Department of Immunology, 3rd Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
- 700 1_
- $a Kozak, Tomas $u Department of Internal Medicine and Haematology, 3rd Faculty of Medicine, Charles University in Prague and Faculty Hospital Kralovske Vinohrady, Srobarova 50, 100 34, Prague 10, Czech Republic.
- 773 0_
- $w MED00006222 $t Clinical and experimental medicine $x 1591-9528 $g Roč. 16, č. 4 (2016), s. 529-537
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26409838 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170413 $b ABA008
- 991 __
- $a 20170427115839 $b ABA008
- 999 __
- $a ok $b bmc $g 1200718 $s 975031
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 16 $c 4 $d 529-537 $e 20150926 $i 1591-9528 $m Clinical and Experimental Medicine $n Clin Exp Med $x MED00006222
- LZP __
- $a Pubmed-20170413
